Invitae Corp. (NVTA)

16.08
0.14 0.88
NYSE : Health Services
Prev Close 15.94
Day Low/High 15.45 / 16.25
52 Wk Low/High 4.35 / 18.38
Avg Volume 1.05M
Exchange NYSE
Shares Outstanding 74.62M
Market Cap 1.19B
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

New Study Finds Disease-Causing Variants More Common In Men With Prostate Cancer Than Previously Thought

New Study Finds Disease-Causing Variants More Common In Men With Prostate Cancer Than Previously Thought

-- Largest Dataset of Prostate Cancer Patients Shows 17% Have Increased Risk Based on Genetic Analysis --

Invitae To Announce Fourth Quarter And Year-end 2018 Financial Results On February 19, 2019

Invitae To Announce Fourth Quarter And Year-end 2018 Financial Results On February 19, 2019

SAN FRANCISCO, Jan. 29, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, today announced that it will report its fourth quarter and year-end 2018 financial results on Tuesday, February 19, 2019 and will...

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

Cronos, Fortinet and Dominion: 'Mad Money' Lightning Round

Cronos, Fortinet and Dominion: 'Mad Money' Lightning Round

Jim Cramer weighs in on Cronos, Fortinet, Dominion Energy and more.

First Week Of February 15th Options Trading For Invitae (NVTA)

First Week Of February 15th Options Trading For Invitae (NVTA)

Investors in Invitae Corp saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVTA options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

Invitae Is Now Oversold (NVTA)

Invitae Is Now Oversold (NVTA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Invitae Breaks Below 200-Day Moving Average - Notable For NVTA

Invitae Breaks Below 200-Day Moving Average - Notable For NVTA

In trading on Friday, shares of Invitae Corp crossed below their 200 day moving average of $10.05, changing hands as low as $9.44 per share. Invitae Corp shares are currently trading down about 9.7% on the day.

Invitae To Present At The 37th Annual J.P. Morgan Healthcare Conference

Invitae To Present At The 37th Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Dec. 20, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 37th Annual J.

Here Are 3 Small-Cap Names for Biotech Investors to Consider

Here Are 3 Small-Cap Names for Biotech Investors to Consider

We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.

New Study Published In Journal Of Clinical Oncology Supports Universal Genetic Testing For All Breast Cancer Patients

New Study Published In Journal Of Clinical Oncology Supports Universal Genetic Testing For All Breast Cancer Patients

-- Data shows current guidelines exclude many patients with medically relevant genetic changes --

Invitae Highlighting New Research, Honoring Excellence In Genetic Counseling At National Society Of Genetic Counselors (NSGC) 37th Annual Conference

Invitae Highlighting New Research, Honoring Excellence In Genetic Counseling At National Society Of Genetic Counselors (NSGC) 37th Annual Conference

-- Research highlights frequency of medically actionable variants among secondary findings --

Invitae Expands Work With Alnylam Pharmaceuticals To Provide Access To Genetic Testing For Primary Hyperoxaluria

Invitae Expands Work With Alnylam Pharmaceuticals To Provide Access To Genetic Testing For Primary Hyperoxaluria

-- Part of Invitae's network of partnerships, program supports early diagnosis to help patients and their clinicians make more informed decisions about their health --

PayPal, Senseonomics, Idexx Laboratories: 'Mad Money' Lightning Round

PayPal, Senseonomics, Idexx Laboratories: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at PayPal, Senseonomics, Idexx Laboratories, Sonos, Denbury Resources, Apptio, Invitae, Wayfair, JD.com, and McDonald's.

The Truth About Trade: Cramer's 'Mad Money' Recap (Monday 9/17/18)

The Truth About Trade: Cramer's 'Mad Money' Recap (Monday 9/17/18)

Jim Cramer says Wall Street isn't very worried about tariffs. He highlights the stocks with China exposure and looks at the potential impact.

First Week Of June 2019 Options Trading For Invitae (NVTA)

First Week Of June 2019 Options Trading For Invitae (NVTA)

Investors in Invitae Corp saw new options begin trading this week, for the June 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Invitae To Announce Third Quarter 2018 Financial Results On November 7, 2018

Invitae To Announce Third Quarter 2018 Financial Results On November 7, 2018

SAN FRANCISCO, Oct. 24, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018 and will host a...

Research Shows High Positive Rate For Risk Of Hereditary Disease In Study Of Proactive Genetic Health Screening For Healthy People

Research Shows High Positive Rate For Risk Of Hereditary Disease In Study Of Proactive Genetic Health Screening For Healthy People

-- Data presented at annual American Society of Human Genetics meeting --

Interesting NVTA Put And Call Options For November 16th

Interesting NVTA Put And Call Options For November 16th

Investors in Invitae Corp saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVTA options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

Consider These Diagnostic Testing Firms

Consider These Diagnostic Testing Firms

Diagnostic firms can have an advantage of recurring revenue streams.

Invitae To Present At The Ladenburg Thalmann 2018 Healthcare Conference

Invitae To Present At The Ladenburg Thalmann 2018 Healthcare Conference

SAN FRANCISCO, Sept. 18, 2018 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Ladenburg Thalmann...

Invitae Appoints Chitra Nayak To Its Board Of Directors

Invitae Appoints Chitra Nayak To Its Board Of Directors

-- Bringing invaluable expertise in scaling transformative businesses throughout her career as a technology industry veteran --

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.

Invitae Reaches Analyst Target Price

Invitae Reaches Analyst Target Price

In recent trading, shares of Invitae Corp have crossed above the average analyst 12-month target price of $12.25, changing hands for $12.56/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

3 Small Biotechs Turn on the Revenue Jets

3 Small Biotechs Turn on the Revenue Jets

BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.

Noteworthy Wednesday Option Activity: NVTA, SPA, ATI

Noteworthy Wednesday Option Activity: NVTA, SPA, ATI

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Invitae Corp , where a total volume of 6,054 contracts has been traded thus far today, a contract volume which is representative of approximately 605,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 77.8% of NVTA's average daily trading volume over the past month, of 778,605 shares.

Interesting NVTA Call Options For July 20th

Investors in Invitae Corp saw new options become available this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVTA options chain for the new July 20th contracts and identified the following call contract of particular interest.

3 of My Favorite Medical Diagnostic Plays

3 of My Favorite Medical Diagnostic Plays

These equities have been in rally mode since April.

3 Favorite Biotech Stocks for the Second Quarter

3 Favorite Biotech Stocks for the Second Quarter

Your questions are answered in our latest addition of the biotech mailbag.

TheStreet Quant Rating: D (Sell)